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I Abstract [ 
A gas chromatography-mass spectrometry method was developed 
for the analy~s of t]unJtrazepam (FN) and its major metabolite, 
7-amino-flunitrazepam (7-amino-FN), in both plasma and whole 
blood. The method was based on acid hydrolysis of the samples after 
dilution with HPLC water followed by extraction and derivatization 
(heptafluorobutyrate) of the resulting benzophenones. Analysis of 
plasma and whole blood samples from subjects administered 2-mg 
doses of FN showed that FN was only detected in whole blood 
(rOD 5 ng/mL) and not in plasma. However, 7-amino-FN was 
detected in both plasma and whole blood, although the levels were 
much higher in plasma. 7-Amino-FN was detected for the entire 
period of specimen collection (12 h), but FN was only detected in 
whole blood for 4 h after ingestion with peak levels after I h. 
the time course of detection of the parent drug versus its metabo- 
lite in both plasma nd blood samples collected at the same time. 
Experimental 
Materials 
7-Amino-FN-ds was purchased from Lipomed, Inc. (Cambridge, 
MA). FN, nor-FN, and 7-amino-FN were obtained from Radian 
Corp. (Austin, TX). 7-Amino-nor-FN was provided by Roche 
Diagnostics Systems (Somerville, N J). All solvents were high-per- 
formance liquid chromatography (HPLC) grade, and the chemi- 
cals were American Chemical Society reagent grade. 
Introduction 
Flunitrazepam (FN), or Rohypnol ~, is a sleeping aid that belongs 
to a group of newer-generation benzodiazepines that are admin- 
istered in small dosage. Although it is not legally available in the 
United States, it has appeared onU.S. streets and been alleged to 
have been involved in some date-rape cases (1,2). 
Studies (3,4) on excretion patterns of FN showed that 7-amino- 
flunitrazeparn (7-arnino-FN) is the most predominant metabolite 
in urine with the parent drug detected in only a few cases. The 
detection window of 7-amino-FN in urine can be extended to at 
least 72 h after ingestion (4). In the meantime, there are some 
questions about he concentration f FN and its metabolites in 
blood. It was reported (5,6) that he concentration f 7-amino-FN 
can greatly exceed that of unchanged parent drug in stored blood 
samples as a consequence of an in vitro reduction of the 7-nitro 
group of FN. In a previous communication (4), we reported on a 
sensitive gas chromatography-mass spectrometry (GC-MS) pro- 
cedure for the analysis of FN metabolites in urine samples to 
detect prior ingestion of the drug. 
Because serum or, more often, blood specimens are commonly 
collected for forensic toxicological analysis, this communication 
was initiated to present a simple extraction method and a sensi- 
tive GC--MS procedure for the detection of both 7-amino-FN and 
FN in both serum (or plasma) and whole blood and to ascertain 
Extraction, hydrolysis, and derivatization 
To 1 mL of plasma or blood sample in a 15-mL centrifuge tube, 
25 I~L of 7-amino-FN-d3 at1 I~g/mL (25 ng/mL of plasma or blood 
concentration) was added. Three milliliters of water (HPLC 
grade) was used to dilute the sample, which was then vortex 
mixed briefly, followed by the addition of 1 mL of concentrated 
HCI. The tube was tightly capped and placed in an oven at 100~ 
for I h. After the tube was taken out of the oven and cooled to 
room temperature, 1.5 mL of 10N KOH was added, and the 
sample was vortex mixed. Six milliliters of chloroform was used to 
extract the sample by shaking ently for 2 min. After the sample 
separated into two layers (centrifugation maybe needed to help 
phase separation), thetop aqueous layer was aspirated to waste. 
The chloroform layer was washed with water twice (1mL each) 
and then poured into a 13 x 100-mm test ube. The solvent was 
evaporated under N2 at 50~ in a water bath. The residue was dis- 
solved in 0.5 mL of chloroform containing 20 IJg/mL of 4-pyrro- 
lidinopyridine, and 100 IJL of heptafluorobutyric anhydride was 
added. The sample was vortex mixed and allowed to stand at room 
temperature (65-75~ for 1 h before the addition of 0.2 mL of 2N 
NaOH and 1 mL of 1.5M carbonate buffer (pH 11). After vortex 
mixing for 30 s, the aqueous layer was aspirated to waste. One 
milliliter of deionized water was added, and the sample was vortex 
mixed for 30 s. The organic layer was then transferred to a GC vial, 
and the solvent was evaporated under N~ at 50~ The residue was 
dissolved in 50 I~L of ethyl acetate for GC-MS analysis. Two 
microliters of sample was injected. 
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Figure 1. Full-scan mass spectra of the heptafluorobutyrate derivatives of FN (A), nor-FN (B), 
7-amino-FN (C), and 7-amino-nor-FN (D). 
Table I. Concentrations (ng/mL) of FN and Metabolites in Blood Collected 
from Two Subjects Administered a Single 2-rag Oral Dose 
Time 7-Amino- 
Subject postdose (h) FN 7-Amino-FN Nor-FN Nor-FN 
A 0 0.00 0.00 0.00 0.00 
A 0.5 5,66 5,13 0.00 0.00 
A 1 8.06 5,89 0.00 0.00 
A 2 6.21 6.06 0.00 0.00 
A 4 < LOD 6.35 < LOD 0.00 
A 8 < LOD 5.78 < LOD 0.00 
A 12 < LOD 5.62 0.00 0,00 
B 0 0.00 0.00 0.00 0,00 
B 0.5 < LOD 1.70 0.00 0.00 
B 1 7.27 2.13 0.00 0.00 
B 2 5.84 3.88 0.00 0.00 
B 4 5.94 5.23 0.00 0.00 
B 8 0.00 5.17 0.00 0.00 
B 12 0.00 4.20 0.00 0.00 
GC-MS conditions 
GC-MS conditions were similar to those used 
in the analysis of urine samples (4) but required 
a relatively onger un time for plasma or blood 
analysis. A Hewlett Packard (Palo Alto, CA) 5890 
GC interfaced with a Hewlett Packard 5970 mass 
selective detector was used. The electron multi- 
plier voltage was set at 200 V above the tune 
value. The GC was equipped with a 25-m x 0.2- 
ram (0.33-pro film thickness) DB-5 MS column 
operated in the splittess mode with purge valve 
closed for 0.2 min. Helium carrier flow was 36.2 
cm/s under 25 psi column head pressure. Oven 
temperature was set at 180~ held for 0.5 rain, 
then increased to 260~ at 20~ where it 
was held for 1 min, then finally increased to 
280~ at 30~ and held for 8 min. The 
injector and detector temperatures were 250 and 
280~ respectively. A Hewlett Packard G1034C 
version C.02.00 ChemStation data system was 
used to record the data. SIM ions for the various 
analytes were as follows (underlined ions are 
quantitation ions): 516 and 639 for 7-amino-FN- 
d3 (Rt = 6.30 rain); 513, 636, and 439 for 7- 
amino-FN (Rt = 6.32 rain); 274 and 257 for 
flunitrazepam (Rt = 8.53 rain); 453, 622, and 499 
for 7-amino-nor-FN (Rt = 5.92 rain); and 456 and 
333 for nor-FN (Rt = 6.20 min). 
Clinical studies 
Four subjects were recruited forthese studies 
with the proper consent forms and protocols 
approved by the institutional IRB. 
Two clinical studies in which two subjects were 
administered a 2-rag oral dose f flunitrazepam 
were conducted. In the first study, blood speci- 
mens were collected from subjects A and B at 0, 
0.5, 1, 2, 4, 8, and 12 h postingestion. In the 
second study, subjects C and Dwere each admin- 
istered a 2-mg dose of flunitrazepam, and blood 
samples were collected at 0, 0.25, 0.5, 1, 2, 4, 8, 
and 12 h after dosing. However, in the second 
study, half of the blood samples were centrifuged 
and the plasma separated for comparison of the 
drug and metabolites level in plasma versus 
whole blood. 
Results and Discussion 
In developing analytical methods for drugs and 
metabolites inplasma or whole blood, extraction 
procedures often involve protein precipitation 
with methanol r acetonitrile. In our efforts to 
develop a procedure for flunitrazepam and its 
metabolites, an initial protein-precipitation step 
was carried out using 3 mL of methanol per 
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milliliter of plasma or whole blood. This was followed by centrifu- 
gation, evaporation of the methanol, and acid hydrolysis of the 
extract. This extraction procedure was only partially successful 
because of the strong protein binding of the analytes. This 
resulted in inconsistent extraction efficiency, and in some cases, 
particularly with whole blood, neither the drugs nor the internal 
standards were recovered. 
Other extraction methods such as liquid-liquid extraction 
using butyl chloride (6,7) and solid-phase extrac- 
tion using Bond-Eiut Certify ~ columns (8) or 
CleanScreen | extraction cartridges (9) produced 
unsatisfactory results for whole blood samples. 
After several trials with different extraction con- 
ditions, a procedure was developed for both 
plasma and whole blood in which 1 mL (plasma or 
whole blood) was diluted with 3 mL of water 
(HPLC grade) first and hydrolyzed with hydro- 
chloric acid directly without separation fthe pro- 
teins. Most of the precipitate formed during the 
hydrolysis redissolved into the aqueous phase 
after basification. The analytes were then parti- 
tioned into CHCI3. Washing twice with water 
resulted in a clean CHC13 extract. This process 
resulted in the formation of specific benzophe- 
nones corresponding tothe individual drug and 
metabolites a previously described y E1Sohly 
et al. (4). These benzophenones are then deriva- 
tized (heptafluorobutyrate) prior to analysis. Full 
scan mass pectra of the derivatized benzophe- 
nones corresponding to FN, nor-FN, 7-amino-FN, 
and 7-amino-nor-FN are shown in Figure 1. 
The average recovery (n = 5) for 7-amino-FN and 
FN in whole blood and plasma was 93% and 53%, 
respectively, at 25 ng/mL This was determined by 
comparing the absolute peak area from extracted 
plasma specimens spiked with the analytes to the 
peak areas ofthe analytes spiked in HPLC-grade 
water at the same levels. The limits of detection 
(LOD) for 7-amino-FN, 7-amino-nor-FN, FN, and 
nor-FN in plasma were 1.0, 1.0, 5, and 5 ng/mL, 
respectively. The LOD was established as the 
lowest concentration of each analyte that provided 
a signal-to-noise ratio greater th n 5 for the quan- 
titation ion with the presence ofthe required con- 
firming ions. The limit of quantitation (LOQ) for o 
all analytes was found to be the same as the LOD. o 
All curves were linear up to at least 100 ng/mL, m "a 
The precision of the method was determined at " 
5 ng/mL of all analytes, and the coefficient ofvari- .n 
ation ranged from 5.1% for 7-amino-FN to 11.7% < 
for FN. 
Figure 2 shows a typical chromatogram from a 
whole blood specimen analyzed by this method, 
with approximately 6 ng/mL 7-amino-FN and 8 
ng/mL FN. 
Concentration of flunitrazepam and metabolites 
in whole blood 
Clinical whole blood samples from two subjects 
(A and B) administered a 2-mg dose of flunitrazeparn were ana- 
lyzed by this method. Table I shows that nor-FN and 7-arnino-nor- 
FN were either too l w to detect or not present. The method was 
able to detect the presence of 7-amino-FN at concentrations 
ranging from 1.70 to 6.35 ng/mL over a 12-h period with t e peak 
concentrations appearing t 4 h.The parent drug, flunitrazepam, 
was also detected between 0.5 h to 4 h with the peak concentra- 
tion appearing at1 h in both subjects. 
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Figure 2. GC--MS SIM chromatograms of a whole blood sample from Subject A at I h. A, 5.89 nglmL 
of AFN; B, 25 nglmL of AFN-d3; and C, 8.06 ng/nL of FN. 
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Table II. Comparison of FN and 7-Amino-FN Concentrations in Blood 
and Plasma 
Whole blood Plasma 
Time FN 7-Amino-FN FN 7-Amino-FN 
Subject (h) (ng/mL) (ng/mL) (ng/mL) (ng/mL) 
C 0 0 0 0 0 
C 0.25 4.60* 0.95 0 2.16 
C 0.5 5.70 1.49 0 4.11 
C 1 6.77 2.83 0 10.4 
C 2 4.64* 2.38 0 12.2 
C 4 < LOD 2.94 0 11.8 
C 8 < LOD 2.93 0 5.21 
C 12 0 3.16 0 6.81 
D 0 0 0 0 0 
D 0.25 0 < LOD 0 < LOD 
D 0.5 < LOD < LOD 0 8.11 
D 1 3.47* 1.00 0 < LOD 
D 2 < LOD 1.67 0 7.58 
D 4 0 2.31 0 10.3 
D 8 0 2.80 0 4.21 
D 12 0 2.80 0 6.74 
*Lower than established LOD but quantitated because these samples howed acceptable ion ratios. 
Comparison of FN and 7-amino-FN concentrations in whole 
blood versus plasma in the same samples 
Blood samples were collected fromtwo subjects (C and D) at dif- 
ferent times after oral ingestion of a 2-rag dose of flunitrazepam. 
Each sample was then divided into two portions. 
One portion was kept as is and used for whole blood analysis. 
The second portion was centrifuged (1000rpm) to separate he 
plasma which was analyzed for FN and 7-amino-FN. This experi- 
ment was carried out to determine the relative levels of FN and 
7-amino-FN in plasma versus whole blood. We have previously 
observed (unpublished data) that FN was absent (below LOD of 10 
ng/mL) in plasma samples. 
Table II shows the concentration f FN and 7-amino-FN in 
whole blood versus plasma from the same samples. The data show 
that FN was present only in whole blood and ot in plasma. 
However, 7-amino-FN was present in both plasma nd whole 
blood, although the levels were much higher in plasma, sug- 
gesting the predominance of the metabolite in plasma versus 
cells, possibly because of matrix effect. 
The absence of FN from plasma samples in this study is not in 
total agreement with previous reports (10,11).This could be due 
to the differences in the sensitivities of the methods u ed 
(GC-electrochemical detection and liquid chromatography-mass 
spectrometry in the previous work with sensitivity of 0.2-1.0 
ng/mL versus GC-MS at 5 ng/mL in this report). However, the 
blood levels found i  this study were in agreement with those 
reported by Bogusz et al. (11) for the clinical samples. 
Conclusions 
The GC-MS procedure described in this communication has a 
high sensitivity to detect flunitrazepam and its 
major metabolite, 7-amino-FN, in plasma and in 
whole blood. The parent drug, however, was only 
detectable in whole blood for approximately 4 h 
after ingestion of 2-rag doses of flunitrazepam, 
whereas 7-amino-FN was detectable for the 
entire period of collection (12 h). Therefore, for 
forensic purposes, detection of FN in whole blood 
would indicate recent ingestion of the drug, and 
7-amino-FN could be monitored for a longer 
period of time. 
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